Prothena Corp. (PRTA) Misses Q1 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. BROS
3. FIS
4. ARM
5. EXPE
6. QCOM
7. DDOG
8. PAYC
9. CHYM
10. CPAY

Go back to Prothena Corp. (PRTA) Misses Q1 EPS by 4c

Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update

May 3, 2016 4:06 PM EDT

Net cash used in operating and investing activities was $25.4 million in the first quarter; strong quarter-end cash position of $474.3 million, including net proceeds of $128.6 million raised through January 2016 public equity offering, supports advancement of multiple clinical development programsInitiated PRONTO, a registration-directed, global Phase 2b trial of NEOD001 in patients with AL amyloidosisInitiated Phase 1b multiple ascending dose, proof-of-biology study of PRX003 in patients with psoriasisAppointed experienced biotechnology executive David B. McNinch as Chief Commercial Officer... More